Mangoceuticals, Inc. (MGRX) 10-Year Financial Performance & Capital Metrics

MGRX • • Industrial / General

HealthcareHealthcare ITTelehealth & Virtual Care PlatformsSpecialized Telehealth Solutions

AboutMangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. Mangoceuticals, Inc. was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.Show more

Revenue $616K -15.8%
EBITDA -$7M +21.1%
Net Income -$9M +5.5%
EPS (Diluted) -4.40 +48.7%
Gross Margin 61.7% +4.6%
EBITDA Margin -1177.27% +6.3%
Operating Margin -1294.42% -2.7%
Net Margin -1413.6% -12.2%
ROE -118.29% +91.1%
ROIC -83.82% +97.3%
Debt/Equity 0.02 -90.7%
Interest Coverage -581.90

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.1x book value

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 4 (bottom 4%)
✗Shares diluted 84.3% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-38.16%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-112.55%

EPS CAGR

10Y-

5Y-

3Y-

TTM50.68%

ROCE

10Y Avg-607.22%

5Y Avg-607.22%

3Y Avg-607.22%

Latest-107.84%

Peer Comparison

Specialized Telehealth Solutions

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
VSEEWVSee Health, Inc.	1.52M	0.09	-0.02	78.42%	-85.76%
VSEEVSee Health, Inc.	14.7M	0.44	-0.08	80.74%	-85.76%
MGRXMangoceuticals, Inc.	10.82M	0.66	-0.15	-15.81%	-42.45%	-126.03%		0.02
BEATHeartBeam, Inc.	75.78M	2.20	-3.01			-50.79%
OMDAOmada Health	906.26M	15.65	-18.41	38.29%	-16.82%	-16.98%		0.47
HNGEHinge Health, Inc.	1.66B	43.76	-291.73	33.37%	-3.06%	-2.83%	2.73%	0.03

Profit & Loss

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	8.94K	731.49K	615.87K
Revenue Growth %	-	-	80.83%	-0.16%
Cost of Goods Sold+	0	4.09K	299.99K	235.91K
COGS % of Revenue	-	0.46%	0.41%	0.38%
Gross Profit+	0	4.85K	431.5K	379.96K
Gross Margin %	-	0.54%	0.59%	0.62%
Gross Profit Growth %	-	-	87.97%	-0.12%
Operating Expenses+	17.52K	2M	9.65M	8.35M
OpEx % of Revenue	-	223.34%	13.19%	13.56%
Selling, General & Admin	17.52K	2M	5.42M	7.9M
SG&A % of Revenue	-	223.34%	7.41%	12.82%
Research & Development	0	0	0	0
R&D % of Revenue	-	-	-	-
Other Operating Expenses	0	0	4.23M	453.79K
Operating Income+	-17.52K	-1.99M	-9.22M	-7.97M
Operating Margin %	-	-222.8%	-12.6%	-12.94%
Operating Income Growth %	-	-112.67%	-3.63%	0.14%
EBITDA+	-17.52K	-1.99M	-9.19M	-7.25M
EBITDA Margin %	-	-222.36%	-12.57%	-11.77%
EBITDA Growth %	-	-112.45%	-3.63%	0.21%
D&A (Non-Cash Add-back)	0	3.86K	24.89K	721.53K
EBIT	-17.52K	-1.99M	-8.12M	-8.69M
Net Interest Income+	-181	-6.47K	0	-13.7K
Interest Income	0	0	0	0
Interest Expense	181	6.47K	0	13.7K
Other Income/Expense	-181	-6.47K	6.47K	-735K
Pretax Income+	-17.7K	-2M	-9.21M	-8.71M
Pretax Margin %	-	-223.52%	-12.59%	-14.14%
Income Tax+	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%
Net Income+	-17.7K	-2M	-9.21M	-8.71M
Net Margin %	-	-223.52%	-12.59%	-14.14%
Net Income Growth %	-	-111.88%	-3.61%	0.05%
Net Income (Continuing)	-17.7K	-2M	-9.21M	-8.71M
Discontinued Operations	0	0	0	0
Minority Interest	0	0	0	-1.08K
EPS (Diluted)+	-0.02	-1.73	-8.58	-4.40
EPS Growth %	-	-96.79%	-3.96%	0.49%
EPS (Basic)	-0.02	-1.73	-8.58	-4.40
Diluted Shares Outstanding	997.67K	1.15M	1.07M	1.98M
Basic Shares Outstanding	997.67K	1.15M	1.07M	1.98M
Dividend Payout Ratio	-	-	-	-

Balance Sheet

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	22.55K	694.61K	818.46K	75.59K
Cash & Short-Term Investments	22.55K	682.86K	739.01K	58.65K
Cash Only	22.55K	682.86K	739.01K	58.65K
Short-Term Investments	0	0	0	0
Accounts Receivable	0	0	0	0
Days Sales Outstanding	-	-	-	-
Inventory	0	0	18.5K	0
Days Inventory Outstanding	-	-	22.51	-
Other Current Assets	0	0	0	16.94K
Total Non-Current Assets+	0	308.68K	232.33K	15.29M
Property, Plant & Equipment	0	291.74K	215.39K	62.3K
Fixed Asset Turnover	-	0.03x	3.40x	9.89x
Goodwill	0	0	0	0
Intangible Assets	0	0	0	15.23M
Long-Term Investments	0	0	0	0
Other Non-Current Assets	0	16.94K	16.94K	0
Total Assets+	22.55K	1M	1.05M	15.37M
Asset Turnover	-	0.01x	0.70x	0.04x
Asset Growth %	-	43.49%	0.05%	13.63%
Total Current Liabilities+	39.27K	260.58K	211.08K	1.43M
Accounts Payable	0	33.67K	140.76K	837.5K
Days Payables Outstanding	-	3.01K	171.27	1.3K
Short-Term Debt	39.27K	167.46K	0	150K
Deferred Revenue (Current)	0	0	0	0
Other Current Liabilities	0	0	0	373K
Current Ratio	0.57x	2.67x	3.88x	0.05x
Quick Ratio	0.57x	2.67x	3.79x	0.05x
Cash Conversion Cycle	-	-	-	-
Total Non-Current Liabilities+	0	128.68K	64.96K	0
Long-Term Debt	0	0	0	0
Capital Lease Obligations	0	128.68K	64.96K	0
Deferred Tax Liabilities	0	0	0	0
Other Non-Current Liabilities	0	0	0	0
Total Liabilities	39.27K	389.26K	276.04K	1.43M
Total Debt+	39.27K	352.87K	128.68K	214.96K
Net Debt	16.72K	-330K	-610.33K	156.31K
Debt / Equity	-	0.57x	0.17x	0.02x
Debt / EBITDA	-	-	-	-
Net Debt / EBITDA	-	-	-	-
Interest Coverage	-96.80x	-307.68x	-	-581.90x
Total Equity+	-16.72K	614.03K	774.75K	13.95M
Equity Growth %	-	37.72%	0.26%	17%
Book Value per Share	-0.02	0.53	0.72	7.05
Total Shareholders' Equity	-16.72K	614.03K	774.75K	13.95M
Common Stock	800	1.34K	2.14K	325
Retained Earnings	-17.7K	-2.02M	-11.23M	-20.81M
Treasury Stock	0	0	0	0
Accumulated OCI	0	0	0	-9.85K
Minority Interest	0	0	0	-1.08K

Cash Flow

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-17.52K	-1.35M	-7M	-4.86M
Operating CF Margin %	-	-150.63%	-9.57%	-7.9%
Operating CF Growth %	-	-75.86%	-4.2%	0.3%
Net Income	-17.7K	-2M	-9.21M	-8.71M
Depreciation & Amortization	0	3.86K	24.89K	731.47K
Stock-Based Compensation	0	234.09K	624.46K	248.68K
Deferred Taxes	0	-151.82K	0	0
Other Non-Cash Items	181	546.54K	1.52M	2.2M
Working Capital Changes	0	18.87K	41.51K	660.38K
Change in Receivables	0	0	0	0
Change in Inventory	0	0	0	0
Change in Payables	0	33.67K	107.09K	696.74K
Cash from Investing+	0	-43.1K	-3.52K	65K
Capital Expenditures	0	-43.1K	-3.52K	0
CapEx % of Revenue	-	4.82%	0%	-
Acquisitions	-	-	-	-
Investments	-	-	-	-
Other Investing	0	0	0	65K
Cash from Financing+	40.07K	2.05M	7.06M	4.13M
Debt Issued (Net)	-	-	-	-
Equity Issued (Net)	-	-	-	-
Dividends Paid	0	0	0	-802.11K
Share Repurchases	-	-	-	-
Other Financing	0	0	1.02M	802.11K
Net Change in Cash	-	-	-	-
Free Cash Flow+	-17.52K	-1.39M	-7M	-4.86M
FCF Margin %	-	-155.46%	-9.57%	-7.9%
FCF Growth %	-	-78.32%	-4.04%	0.31%
FCF per Share	-0.02	-1.20	-6.52	-2.46
FCF Conversion (FCF/Net Income)	0.99x	0.67x	0.76x	0.56x
Interest Paid	0	0	0	0
Taxes Paid	0	0	0	0

Key Ratios

Metric	2021	2022	2023	2024
Return on Equity (ROE)	-	-669.02%	-1326.69%	-118.29%
Return on Invested Capital (ROIC)	-	-1051.76%	-3083.5%	-83.82%
Gross Margin	-	54.26%	58.99%	61.7%
Net Margin	-	-22352.11%	-1259.4%	-1413.6%
Debt / Equity	-	0.57x	0.17x	0.02x
Interest Coverage	-96.80x	-307.68x	-	-581.90x
FCF Conversion	0.99x	0.67x	0.76x	0.56x
Revenue Growth	-	-	8083.16%	-15.81%

Frequently Asked Questions

Growth & Financials

Mangoceuticals, Inc. (MGRX) reported $0.5M in revenue for fiscal year 2024.

Mangoceuticals, Inc. (MGRX) saw revenue decline by 15.8% over the past year.

Mangoceuticals, Inc. (MGRX) reported a net loss of $19.8M for fiscal year 2024.

Dividend & Returns

Yes, Mangoceuticals, Inc. (MGRX) pays a dividend with a yield of 61.04%. This makes it attractive for income-focused investors.

Mangoceuticals, Inc. (MGRX) has a return on equity (ROE) of -118.3%. Negative ROE indicates the company is unprofitable.

Mangoceuticals, Inc. (MGRX) had negative free cash flow of $5.9M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener